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Background: The prevalence of Coronary artery disease (CAD) in India has increased consid-
erably over the past few years and could become the number one killer disease if interven-
tions are not done. Factor V Leiden (FVL) mutation and FII G20210A polymorphism are two
recently described genetic factors with a propensity towards venous thrombosis. This
warrants the investigations for thrombophilia in myocardial infarction patients in India.
Methods: The study cohort consisted of 51 patients aged below50 years presentingwith acute
coronary syndromes. In both patient group and normal individuals the major risk factors
Protein C deficiency, Protein S deficiency, anticardiolipin antibodies, Fibrinogen and
Lipoprotein [a] were studied. Factor V Leiden (FVL) G1691A mutation in both control
and patient group was looked by using Polymerase chain reaction (PCR) followed by
sequencing of the PCR products.
Results: Our results indicated significantly higher levels of anticardiolipin antibodies and
fibrinogen in the patients and absence of FVL (G1691A) mutation in our study cohort. One of
the patients (H5) showed insertion of an extra A nucleotide in exon 10 of the Factor V gene
resulting in frame shift mutation in this patient.
Conclusion: The results of present study showed absence of FVL mutation in our population.
However, there is a need to confirm the above findings on patients from different pop-
ulations from different parts of the country. The insertion of an extra A in exon 10 in the
patient needs to be ascertained to confirm that it is one of its kinds or is prevalent in the
population.
Copyright ª 2012, Cardiological Society of India. All rights reserved.1. Introduction leading causes of death in developed countries. ConsiderableArterial thrombosis is a central pathologic mechanism
contributing to myocardial infarction and stroke, together the8133.
(D. Rajasekhar).
2012, Cardiological Socieprogress has been made over the past 10 years in identifying
important genetic risk factors underlying predisposition to
venous thrombosis.1ty of India. All rights reserved.
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coagulant pathways have been explained, and several genetic
risk factors for venous thrombosis have been identified. These
genetic risk factors affect the natural anticoagulant mecha-
nisms and result in a hypercoagulable state due to an imbal-
ance between procoagulant and anticoagulant forces.
Thrombosis is a lifelong risk, and thrombotic events tend to
occur when one or more of the circumstantial risk factors
come into play. It is a typical multifactorial disease, with the
pathogenesis involving both environmental and genetic
mechanisms.2 The three most common genetic thrombo-
philias known to predispose to venous thrombosis are Factor
V G1691A (FV Leiden) (FVL), Methylenetetrahydrofolate
reductase (MTHFR) mutation and Factor II (FII) gene mutation.
FVL, FII G20210A and MTHFR C677T mutations are currently
the most common known genetic risk factors for venous
thrombosis among Caucasians.3e5
In FII G20210A, a GeA transition at position 20210 of the
30untranslated region of the Factor II gene has been found to
be associated with increased prothrombin level and a 3-fold
increase in the risk for venous thrombosis in heterozygotes.
The homozygous state for the CeT transition at position 677 of
MTHFR gene is associated with hyperhomocysteinemia which
predisposes to thrombosis.6e8 Another risk factor in MTHFR
gene is known as A1298C mutation.9 The contribution of
mutations in the prothrombin (FII G20210A), methylenete-
trahydrofolate reductase (C677T) genes and Factor V Leiden
(FVL) to the pathogenesis of arterial thrombosis remains
controversial.
However, similar insight into the genetic component of
arterial thrombosis predisposition has not materialized,
despite considerable effort. Though there is a significant
genetic component to both forms of thrombosis, there
appears to be little overlap among the known genetic risk
factors for venous thrombosis and those predisposing to
arterial thrombosis. In FVL G1691A, arginine is substituted by
glutamine at amino acid residue in 506th position of coagu-
lation Factor V due to this substitution, Factor Va becomes
resistant to degradation by activated Protein C, resulting in
a 3e5-fold increase in the risk of venous thromboembolism in
heterozygous individuals.10,11 Another risk factor in Factor V
gene is FV H1299R.4,9 In a study in northern part of India FVL
and prothrombin G20210A mutations were observed with an
allele frequency 2%,12 therefore, in the present study the
prevalence of FVL (G1691A) mutation an important genetic
cause of thromboembolism was studied in subjects of Raya-
laseema region of India.2. Materials and methods
2.1. Study population
Fifty-one consecutive patients aged below 50 years having
acute coronary syndromes (diagnosed by ECG abnormalities
and elevated cardiac enzymes) like unstable angina and
myocardial infarction (STEMI/NSTEMI), admitted in the
Department of Cardiology, Sri Venkateswara Institute of
Medical Sciences hospital during the period August 2005eJuly
2008 were recruited into the study cohort. Patients of chronicstable angina, patients with other co-morbid conditions
(renal, lung, liver, CNS, pregnancy and other systemic illness)
and patients unwilling to participate in the study were
excluded. Fifty age and sex matched voluntary blood donors
without documented risk factors were recruited into the
control group. An informed consent was taken from each of
the patients and controls following ethical guidelines of the
1975 declaration of Helsinki. This study was approved by the
Institutional Ethical Committee of Sri Venkateswara Institute
of Medical Sciences, Tirupati, Andhra Pradesh, India.
2.2. Baseline assessment
History, physical examination and cardiovascular examina-
tions were done in all patients. Risk factors like diabetes
mellitus, hypertension, smoking, obesity and family history of
premature coronary artery diseasewere assessed. BMI>25 kg/
m2 was considered as obese in the present study.13
2.3. Laboratory measurements
Ten ml of peripheral venous blood was drawn from each
patient after stabilization. Three ml of blood was transferred
into a vial containing 3.2% tri-sodium citrate solution and the
separated plasmawas used for the estimation of Protein C and
Protein S levels by ELISA technique (using Diagnostica Stago,
France). Twoml of bloodwas transferred into a vial containing
heparin and the separated plasmawas used for the estimation
of fibrinogen by Immunoturbidimetry method (using Tulip
Diagnostics, India). Three ml of blood was transferred into
a plain vial and the separated serum was used for the esti-
mation of Lipoprotein [a] (Lp [a]) by Immunoturbidimetry
method (using Daiichi Chemicals, Japan) and anticardiolipin
antibodies (aCL) by ELISA method (using Hycor Biochemical
laboratories, USA). The remaining blood was transferred into
a vial containing EDTA (0.05 M) which was used for DNA
analysis. The separated DNA samples were stored at 20 C
till the assays were done. Fasting lipid profile (total choles-
terol, HDL-cholesterol, triglycerides) was done within 24 h for
all patients using enzymatic kits on Beckman auto analyzer.
LDL-Cholesterol (LDLC) was computed with the Friedewald
formula.14 The cut-off values were 200 mg/dl for total
cholesterol (TC), 130 mg/dl for LDLC, 40 mg/dl for HDL-
Cholesterol (HDLC) and 150 mg/dl for triglycerides.
2.4. Genetic analysis of Factor V
The genomic DNA was extracted from all the blood samples
following the standard protocol mentioned by Sambrook and
Russel.15 This DNA was used as template for amplification of
the exon 10 of the Factor V gene.
2.5. Polymerase chain reaction
Primers for Factor V were designed from the total Factor V
gene sequence released in the database Genbank Accession
No. Z99572.16 Factor V gene amplification was carried out by
polymerase chain reaction using Master cycler gradient
thermo cycler (Eppendorf, Germany) with forward primer:
50-ACCCACAGAAAATGATGCCCAG-30 and reverse primer:
Table 1 e Demographic and clinical information of
patients with acute coronary syndrome.
Risk factor ACS patients [N ¼ 51]
Age
35 and below 40%
Above 35 60%
Gender
Male 86%
Female 14%
Diagnosis
AWMI 35 (69%)
IWMI 9 (17%)
USA 7 (14%)
Hypertension 17 (33%)
Diabetes mellitus 13 (25%)
Smoking 26 (51%)
Dyslipidemia 34 (67%)
Obesity 17 (33%)
Family history 2 (4%)
ACS, Acute coronary syndromes; AWMI, Anterior wall myocardial
infarction; IWMI, Inferior wall myocardial infarction; USA,
Unstable angina.
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5 min at 92 C for initial denaturation; 40 s at 66 C for
annealing; 60 s at 72 C for primer extension and final exten-
sion of 10 min at 72 C. Further analysis of PCR products were
carried out through Single Strand Conformation Poly-
morphism (SSCP).17 The PCR products which showed consid-
erable variations in the SSCP gels were sequenced following
dye termination method adopted from Sanger Institute at
a commercial laboratory (Xcelris Labs Ltd., Ahmedabad, India)
and were compared with the existing sequence of Factor V
gene in the database.
2.6. Statistical analysis
Descriptive statistics include mean and standard error of
mean (SEM) for continuous variables and proportions for
categorical variables were calculated. The strength of the
association between traditional and thrombotic risk factors,
acute coronary syndromes at young age was estimated by
calculating the odds ratios and 95% confidence intervals.
Some of the continuous variables showed skewness and
hence a non-parametric test, ManneWhitney U test, was used
to compare means. Categorical variables were compared by
using Chi-square test. Association between variables was
ascertained by using linear regression analysis. Relation
between dependent variables and independent variables was
found with logistic regression analysis. All computation and
statistical analysis were done using SPSS version 13.0, SPSS
Inc. Chicago, USA.Table 2 e Blood biochemistry of patients with acute
coronary syndrome.
Risk factor Male Female p-value
Mean  SEM Mean  SEM
Total cholesterol (mg/dL) 193.79  8.88 190.00  11.80 0.877
HDLC (mg/dL) 46.55  1.14 48.00  3.14 0.661
Triglycerides (mg/dL) 156.93  11.68 114.25  22.16 0.195
LDLC (mg/dL) 116.17  8.63 119.15  5.83 0.899
Haemoglobin (gm/dL) 13.53  0.32 9.49  0.78 <0.001**
Serum creatinine (mg/dL) 1.05  0.04 0.81  0.05 0.029*
Serum urea (mg/dL) 25.85  1.50 28.00  3.81 0.611
HDLC, High density lipoprotein cholesterol; LDLC, Low density
lipoprotein cholesterol.
* Indicates p-value <0.05.
** Indicates p-value <0.001.3. Results
In our study consisting of 51 patients of acute coronary
syndrome, 35 (69%) had anterior wall infarction (AWMI), 9
(17%) had inferior wall infarction (IWMI) and 7 (14%) had
unstable angina (USA). In the present study the following risk
factors were observed in subjects: 26 (51%) patients were
smokers, 13 (25%) were diabetic, 17 (33%) were hypertensive,
34 (67%) were having dyslipidemia, 17 (33%) were obese and 2
(4%) patients were reported to have family history of CAD. In
the present study 86% of the patients were males. The
demographic and clinical information of the patients with
acute coronary syndromes was summarized in the Table 1.
Among the thrombotic profile that we have studied Protein C
was found to be deficient in 18% of the cases, Protein S was
deficient in 14% of the cases. The levels of Lp [a] were found to
be high in 16%, fibrinogen was high in 55% of cases and aCL
were positive in 43% of cases. Multiple thrombotic risk factors
were found in 37% of the cases and 4% in controls. The lipid
profile of patients of this study is summarized in Table 2.
A total of 19 patients (37%) had the presence of more than
one thrombotic marker in combination. Out of these, 12 had
the presence of two markers in combination and 7 had three
thrombotic markers in combination. Only 2 controls had two
thrombotic markers in combination. Combined thrombotic
risk factors were significant in cases in comparison to controls
(p < 0.001). Protein C levels were found to be deficient in cases
as compared to controls [(Mean  SEM) 82.81  2.90 vs
96.80  3.00 respectively; p ¼ 0.001] whereas aCL levels werefound to be higher in cases as compared to controls
[10.66  0.83 vs. 2.71  0.55 respectively; p < 0.001]. Fibrinogen
levels were also found to be higher in cases as compared to
controls [432.39  32.67 vs 295.12  17.58 respectively;
p < 0.001]. No difference was found in the levels of Protein S
and Lp [a]. Among the studied thrombotic risk factors, aCL
(IgG) was found to be highly associated with the risk of acute
coronary syndrome (OR 1.5; 95% CI, 1.2e1.7; P < 0.001), fol-
lowed by fibrinogen (OR 1.005; 95% CI, 1.002e1.009; P ¼ 0.004)
and then by Protein C (OR 0.95; 95% CI, 0.92e0.99; P ¼ 0.03)
(Table 3).
Chromosomal DNA was isolated from both the cases
and controls for genetic analysis. The present protocol
adopted, yielded good amount of DNA with least shearing.
The extracted DNA was used for amplification of exon 10
of coagulation Factor V (FV) gene. The PCR amplified
products both in the patients and in controls (Fig. 1) were
Table 3 e Thrombotic risk factors in cases and controls.
Thrombotic
risk factors
Cases Controls p-value
Mean  SEM Mean  SEM
Protein C deficiency (%) 82.81  2.90 96.80  3.00 0.001**
Protein S deficiency (%) 94.47  4.06 97.33  3.52 0.596
aCL-IgG (GPL U/mL) 10.66  0.83 2.71  0.55 <0.001**
Lp [a] (mg/dL) 14.50  1.70 13.20  1.34 0.551
Fibrinogen (mg/dL) 432.39  32.67 295.12  17.58 <0.001**
Combined
thrombophilia
1.31  0.90 0.34  0.55 <0.001**
ManneWhitney U test was used for non-parametric variables. aCL,
anticardiolipin antibodies; Lp [a], Lipoprotein [a].
** Indicates p-value <0.001.
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variation in the nucleotide sequence. The SSCP mobility
pattern of exon in the patient showed distinct variation
from the normal. These results were further analyzed by
subjecting these PCR products to dye terminating
sequencing at Xcelris labs Ltd, Ahmedabad. The sequences
obtained were deposited in the GenBank, National centre
for Biotechnology Information (NCBI), Bethesda, Maryland,
USA. Accession numbers are GQ354888, GQ354889,
GQ354890, GQ354891 and GQ354892.
All the sequences of the exon 10 of FV along with control
were analyzed to find anymutation in the sequence. The SSCP
analysis and DNA sequencing showed the absence of FVL
mutation in the case cohort as well as in the controls. In all the
patients the sequences matched with existing FV gene
sequence with no distinct variation either in the gene
sequence or in the protein sequence. Although, the study
group was small yet absence of FVL (G1691A) which is in
consistent in this part of country therefore this variant cannot
be considered as independent risk factor or as a predictor for
CAD. However one of the patients (H5) with unstable angina
had a distinct mutation in exon 10 of the FV gene where one A
nucleotide was inserted resulting in a frame shift mutation in
FV gene (Fig. 2).Fig. 1 e 1% Agarose gel showing PCR products of Exon 10 of
Factor V: 1% agarose gel showing PCR products (223bp)
amplified from the isolated DNA samples. Lane M:
Molecular size marker; Lanes H5, H10, H33, H36: PCR
products of patients; Lane C: PCR product of control.
Fig. 2 e Chromatogram of the exon 10: Chromatogram of
the sequence showing mutated region compared to
normal sequences. The arrow-marked region shows new
mutation in the exon 10.4. Discussion
Venous thromboembolism is a major medical problem,
affecting 1e5 individuals per 1000 annually.6,18 In the past
50 years, the molecular bases of both blood coagulation and
the anticoagulant pathways have been explained, and
several genetic risk factors for venous thrombosis have been
identified. These genetic risk factors affect the natural
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state due to an imbalance between procoagulant and antico-
agulant forces. It is a typical multifactorial disease, with the
pathogenesis involving both environmental and genetic
mechanisms.18 In the present study the prevalence of FVL
mutation (G1691A) an important genetic cause of thrombo-
embolism was evaluated along with other major risk factors,
Protein C, Protein S, aCL, fibrinogen and Lp [a] in subjects from
Rayalaseema region of India.
Among the studied thrombotic risk factors aCL and
fibrinogen levels were significantly elevated in patients
compared with controls. Also, Protein C levels were found to
be associated with the risk of acute coronary syndrome.19e21
Lp [a] is composed of low density lipoprotein particle linked
to apolipoprotein B-100 which also stimulates the secretion of
Plasminogen activator inhibitor (PAI) which interferes with
fibrinolysis and thereby causes atherosclerotic plaque in the
arteries.22 However, in the present study Lp [a] was not
significantly elevated in patients as compared to controls.
The role of FVL as a major genetic risk factor associated
with CAD has been proved in Western population.2,4,7
However, its prevalence in India is highly variable in
different populations. A study in the North Indian population
showed clear absence of FVL in North Indian population.23
However, in another study low prevalence of FVL was
observed in North Indian population.12 Whereas, a study in
Tamilian population in Southern part of India showed no
significant role of FVL and FII Single Nucleotide Poly-
morphisms (SNP).24 In our study also absence of FVLmutation
was observed which is consistent with other reports in this
part of the country. Interesting results were observed in one
patient (H5) who presented with unstable angina showed
insertion of A nucleotide in exon 10 of the Factor V gene
resulting in frame shift mutation in this patient (Fig. 2).
Although this is a newmutation only observed in one patient,
it further needs to be ascertained that this SNP is only
confined to this patient or present in the family and in turn
distributed in the population.5. Conclusion
The inherited thrombophilia is caused by several factors of
them Factor V Leiden (FVL) and prothrombin mutations are
thought to be most frequent in occurrence. However, contri-
bution of these factors varies from population to population.
The prevalence of FVL in Indian population is quiet interesting
although its low occurrence in northern part of India is well
documented. However, in southern part its relevance is not
significantly proven. In consistence with the observation in
the present study we did not find presence of FVL in our study
cohort. Although, the study group was primarily consisted of
patients of middle aged and young patients which was very
small yet the study showed higher levels of anticardiolipin
antibodies and fibrinogen, Protein C levels were deficient
compared to controls and low levels of lipoprotein [a] and
Protein S. Occurrence of a novel insertional mutation A in
exon 10 of Factor V gene in a patient may not be that signifi-
cant in terms of the study group however if the same study isexploited in a large group may through new insights in the
involvement of thromboembolic factors in ACS.Limitations
Sample size of this study is small.Financial support
None.Conflicts of interest
All authors have none to declare.
Acknowledgement
None.r e f e r e n c e s
1. Crowther MA, Kelton JG. Congenital thrombophilic states
associated with venous thrombosis: a qualitative overview
and proposed classification system. Ann Intern Med.
2003;138:128e134.
2. Renaud C, Tardy-Poncet B, Presles E, Chabrier S. Low
prevalence of coagulation F2 and F5 polymorphisms in
mothers and children in a large cohort of patients with
neonatal arterial ischemic stroke. Br J Haematol.
2010;150:709e712.
3. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and
factor V mutations in women with a history of thrombosis
during pregnancy and the puerperium. N Engl J Med.
2000;342:374e380.
4. Auro K, Alanne M, Kristiansson K, et al. Combined effects of
thrombosis pathway gene variants predict cardiovascular
events. PLoS Genet. 2007;3:e120.
5. Koksal V, Baris I, Etlik O. Primer-engineered multiplex PCR-
RFLP for detection of MTHFR C677T, prothrombin G20210A
and factor V Leiden mutations. Exp Mol Pathol. 2007;83:1e3.
6. Ma¨rz W, Nauck M, Wieland H. The molecular mechanisms of
inherited thrombophilia. Z Kardiol. 2000;89:575e586.
7. Friedline JA, Ahmad E, Garcia D, et al. Combined Factor V
Leiden and prothrombin genotyping in patients presenting
with thromboembolic episodes. Arch Pathol Lab Med.
2001;125:105e111.
8. Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N,
Inbal A. Prevalence of genetic markers for thrombophilia in
recurrent pregnancy loss. Hum Reprod. 2002;17:1633e1637.
9. Coulam CB, Wallis D, Weinstein J, DasGupta DS,
Jeyendran RS. Comparison of thrombophilic gene mutations
among patients experiencing recurrent miscarriage and deep
vein thrombosis. Am J Reprod Immunol. 2008;60:426e431.
10. Dahlbaeck B, Carlsson M, Svensson PJ. Familial thrombophilia
due to a previously unrecognized mechanism characterized
by poor anticoagulant response to activated protein C:
prediction of a cofactor to activated protein C. Proc Natl Acad
Sci USA. 1993;90:1004e1008.
i n d i a n h e a r t j o u rn a l 6 4 ( 2 0 1 2 ) 5 7 0e5 7 5 57511. Koster T, Rosendaal FR, de Ronde H, Briet E,
Vandenbroucke JP, Bertina RM. Venous thrombosis due to
poor anticoagulant response to activated protein C: Leiden
thrombophilia study. Lancet. 1993;342:1503e1506.
12. Kumar SI, Kumar A, Srivastava S, Saraswat V, Aggarwal R.
Low frequency of factor V Leiden and prothrombin G20210A
mutations in patients with hepatic venous outflow tract
obstruction in northern India: a case-control study. Indian J
Gastroenterol. 2005;24:211e215.
13. International Obesity Task Force (on behalf of the Steering
Committee). The Asia-Pacific Perspective: Redefining Obesity and
Its Treatment. Sydney, Australia: Western Pacific Region
Health Communications Australia Pty Limited; 2002.
14. Friedewald WT, Levy RJ, Fredrickson DS. The concentration of
LDL-cholesterol in plasma without the preparative
ultracentrifuge. Clin Chem. 1972;8:499.
15. Sambrook J, Russel WD. Molecular Cloning. 3rd ed. New York:
Cold Spring Harbor Laboratory; 2001.
16. Bird C. Homo sapiens. Coagulation Factor V (FV) on
chromosome 1q23. ACCESSION Z99572. http://www.ncbi.nlm.
nih.gov/entrez/view.
17. Sunnucks P, Wilson AC, Behereqaray LB, Zenger K, French J,
Taylor AC. SSCP is not so difficult: the application and utility
of single-stranded conformation polymorphism inevolutionary biology and molecular ecology. Mol Ecol.
2000;9:1699e1710.
18. Dahlba¨ck B. Advances in understanding pathogenic
mechanisms of thrombophilic disorders. Blood.
2008;112:19e27.
19. Mishra MN, Kalra R, Gupta MK. Antiphospholipid antibodies
in young myocardial infarction patients. Indian J Biochem
Biophys. 2007;44:481e484.
20. Jose J, Selvakumar D, Selvakumar R, Kanagasapabathy AS,
Jeyaseelan L. Plasma fibrinogen e an independent risk factor
for ischaemic heart disease. Indian Heart J. 1998;50:45e48.
21. Ganapathyraman L, Shanthi P, Baba Krishnan K, Madhvan M,
Lakshmikanthan C. Protein C levels in ischaemic heart
disease. Indian Heart J. 1996;48:125e127.
22. Gambhir JK, Kaur H, Gambhir DS, Prabhu KM. Lipoprotein (a)
as an independent risk factor for coronary artery disease in
patients below 40 years of age. Indian Heart J. 2000;52:411e415.
23. Gupta N, Khan F, Tripathi M, et al. Absence of factor V Leiden
(G1691A) mutation, FII G20210A allele in coronary artery
disease in North India. Indian J Med Sci. 2003;57:535e542.
24. Angeline T, Bentley HA, Hawk AB, et al. Prevalence of the
Factor V G1691A and the Factor II/prothrombin G20210A gene
polymorphisms among Tamilians. Exp Mol Pathol.
2005;79:9e13.
